Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745119 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 994
- Enrollment target
NCT02745119 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 994 participants.
The verdict
NCT02745119, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 994 participants
- Enrollment target
Study Summary
This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.
Interventions
- DRUG Lampalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 994 participants |
| Start Date | 2016-07-21 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02745119
The ClinicalTrials.gov registry entry for NCT02745119 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 994 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lampalizumab is the first listed.
NCT02745119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02745119 about?
NCT02745119 is a clinical study titled "Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)". This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT0224...
What is the current status of trial NCT02745119?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 994 participants. The study started on 2016-07-21. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02745119?
The interventions under investigation include: Lampalizumab (DRUG).
Who is sponsoring clinical trial NCT02745119?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.